Iambic Therapeutics Inc., a clinical-stage biotech firm specializing in cancer treatments, successfully completed its US initial public offering (IPO), raising $150 million. The company sold approximately 9.38 million shares at $16 each, pricing the offering at the midpoint of its targeted range of $15 to $17 per share.
The IPO marks a significant milestone for Iambic, which leverages artificial intelligence to develop new cancer drugs. Notably, Nvidia Corp. is among the company's key shareholders, highlighting the intersection of cutting-edge technology and pharmaceutical innovation.
Iambic's decision to price its shares at $16 reflects a balanced approach, aiming to attract investors while maintaining strong market positioning. The funds raised will likely support the company's ongoing clinical trials and research initiatives.